International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Down 40.5% in March

International Stem Cell Corp. (OTCMKTS:ISCO) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 3,010 shares, a drop of 40.5% from the March 15th total of 5,058 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 5,405 shares, the short-interest ratio is currently 0.6 days.

International Stem Cell Trading Up 11.0%

ISCO traded up $0.01 during midday trading on Wednesday, hitting $0.15. 1,173 shares of the company were exchanged, compared to its average volume of 7,184. The company’s 50 day simple moving average is $0.15 and its 200 day simple moving average is $0.15. The firm has a market capitalization of $1.20 million, a price-to-earnings ratio of -2.50 and a beta of 0.05. International Stem Cell has a 1-year low of $0.11 and a 1-year high of $0.27.

International Stem Cell (OTCMKTS:ISCO) last released its quarterly earnings data on Monday, March 30th. The biotechnology company reported ($0.04) earnings per share for the quarter. The business had revenue of $2.15 million during the quarter.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.